BVT Put 80 NOVN 20.12.2024/ DE000VM3V7X4 /
10/9/2024 8:56:57 AM | Chg.- | Bid10:00:36 PM | Ask10:00:36 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.039EUR | - | - Bid Size: - |
- Ask Size: - |
NOVARTIS N | 80.00 CHF | 12/20/2024 | Put |
GlobeNewswire
7/30
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
7/8
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire
6/26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
6/13
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
4/16
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
4/11
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
3/14
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
2/28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
2/28
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
1/10
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
1/5
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
1/2
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...